Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SURVIVE: Cangrelor for ACS-related Cardiogenic Shock/Cardiac Arrest on VA-ECMO
NCT06792643Phase 2Recruiting
- Sponsor
- IRCCS Ospedale San Raffaele
- Start
- Apr 2024
- Primary completion
- Oct 2025
- Modality
- Nucleic Acid-Directed Small Molecules, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cangrelor in acute coronary syndrome (ACS), cardiogenic shock and cardiac arrest (SCA), sponsored by IRCCS Ospedale San Raffaele. Primary endpoints: Major bleeding (BARC type 3b or 5), Thrombotic events and 1 more. Started Apr 2024; status: recruiting.
02
Drugs
cangrelor
03
Conditions
acute coronary syndrome (ACS)cardiogenic shockcardiac arrest (SCA)
Beyond the preview
Go deeper on NCT06792643.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06792643.